AU2005237788A1 - Indole and azaindole derivatives with antitumor action - Google Patents

Indole and azaindole derivatives with antitumor action Download PDF

Info

Publication number
AU2005237788A1
AU2005237788A1 AU2005237788A AU2005237788A AU2005237788A1 AU 2005237788 A1 AU2005237788 A1 AU 2005237788A1 AU 2005237788 A AU2005237788 A AU 2005237788A AU 2005237788 A AU2005237788 A AU 2005237788A AU 2005237788 A1 AU2005237788 A1 AU 2005237788A1
Authority
AU
Australia
Prior art keywords
dimethoxy
indole
phenyl
methoxyphenyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005237788A
Other languages
English (en)
Inventor
Paolo Celestini
Carlo Farina
Stefania Gagliardi
Paola Misiano
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
NiKem Research SRL
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
NiKem Research SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, NiKem Research SRL filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Publication of AU2005237788A1 publication Critical patent/AU2005237788A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2005237788A 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action Abandoned AU2005237788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2004A000874 2004-04-30
IT000874A ITMI20040874A1 (it) 2004-04-30 2004-04-30 Derivati indolici ed azaindolici con azione antitumorale
PCT/EP2005/051908 WO2005105213A2 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Publications (1)

Publication Number Publication Date
AU2005237788A1 true AU2005237788A1 (en) 2005-11-10

Family

ID=34968098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005237788A Abandoned AU2005237788A1 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Country Status (7)

Country Link
US (1) US20070248672A1 (enExample)
EP (1) EP1750687A2 (enExample)
JP (1) JP2007535520A (enExample)
AU (1) AU2005237788A1 (enExample)
CA (1) CA2564249A1 (enExample)
IT (1) ITMI20040874A1 (enExample)
WO (1) WO2005105213A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
CA2951295C (en) * 2007-04-16 2020-04-28 Abbvie Inc. 7-nonsubstituted indole mcl-1 inhibitors
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP5687704B2 (ja) * 2009-10-07 2015-03-18 カロ バイオ アクチェブラーグ 新規エストロゲン受容体リガンド
HRP20161092T1 (hr) 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
AU2013232066B2 (en) 2012-03-16 2017-07-06 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
LT2825542T (lt) 2012-03-16 2016-12-27 Vitae Pharmaceuticals, Inc. Kepenų x receptoriaus moduliatoriai
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
ES2734479T3 (es) * 2012-09-21 2019-12-10 Vivolux Ab Medios y métodos para tratar tumores sólidos
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
MA38569A1 (fr) * 2013-04-23 2017-03-31 Esteve Labor Dr Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MX389753B (es) * 2015-06-17 2025-03-20 Pfizer Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
US11866409B2 (en) 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
UY39579A (es) 2020-12-22 2022-07-29 Novartis Ag COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105140A (en) * 1870-07-05 Improvement in cigar-wrapping machines
DE2005845A1 (de) * 1969-02-12 1970-09-03 Sumitomo Chemical Company, Ltd., Osaka (Japan) Verfahren zur Herstellung von Benzodiazepinen und ihren Salzen
CA1012147A (en) * 1972-09-25 1977-06-14 Hoffmann-La Roche Limited Indolo quinoline derivatives
AR205437A1 (es) * 1972-09-25 1976-05-07 Hoffmann La Roche Procedimiento para la preparacion de derivados de indoloquinolinona
US4225711A (en) * 1978-10-02 1980-09-30 Schering Corporation Substituted 2-[(methylsulfinyl)acetyl]-3-heterocyclicindoles and their use as immunosuppressants
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
GB9319100D0 (en) * 1993-09-15 1993-11-03 Pfizer Ltd 3-(3-pyridinyl)h-indoles
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
US20020128292A1 (en) * 2000-12-07 2002-09-12 Cai Sui Xiong Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002302248B2 (en) * 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles

Also Published As

Publication number Publication date
JP2007535520A (ja) 2007-12-06
WO2005105213A3 (en) 2006-06-22
WO2005105213A2 (en) 2005-11-10
ITMI20040874A1 (it) 2004-07-30
EP1750687A2 (en) 2007-02-14
CA2564249A1 (en) 2005-11-10
US20070248672A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AU2005237788A1 (en) Indole and azaindole derivatives with antitumor action
TWI306860B (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
EP3154957B1 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
ES2819448T3 (es) Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
CN105452257B (zh) 新型稠合嘧啶化合物或其盐
CN102307870B (zh) Vegf-r2的吡啶氧基吲哚类抑制剂及其用于治疗疾病的用途
EP2829539B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
Biersack et al. Indole compounds against breast cancer: recent developments
JP5425060B2 (ja) ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
CN103237799A (zh) 杂环衍生物、制备方法及其药学用途
JP2005511540A (ja) インドリノン化合物を用いる急性骨髄性白血病の治療
Baytas Recent advances in combretastatin A-4 inspired inhibitors of tubulin polymerization: an update
US8153630B2 (en) Kinase inhibitors
TW201339150A (zh) 新穎哌啶化合物或其鹽
WO2021057867A1 (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
Ren et al. Design and synthesis of novel spirooxindole–indenoquinoxaline derivatives as novel tryptophanyl-tRNA synthetase inhibitors
EP3632443A1 (en) Anti-tumor effect potentiator using novel biphenyl compound
AU2010333083B2 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
CA3233398A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
CN109310672B (zh) σ受体配体在癌症中的用途
WO2024121256A1 (en) Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
HK40065706B (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
HK40065706A (zh) 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
WO2024094163A1 (zh) 多环并环衍生物、其制备方法和应用
HK1198164B (en) 3,5-disubstituted alkynylbenzene compound and salt thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application